Amphivena to expand clinical program, T cell engager pipeline with $62M series C

Amphivena Therapeutics Inc. will use its $62 million series C to advance its lead candidate in solid tumors and build out its T cell engager portfolio. The round, closed Tuesday, was co-led by new investors NanoDimension

Read the full 361 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE